ibrutinib,venetoclax
abbvie,janssen,roche
['nct02910583', 'leusm', 'cll', ' ibru', 'captivate study', 'glow']
#captivate i+v seems feasible in #cll patients achieving umrd after 2y of fix duration treatment also in genetic high risk patients #ash22 #cllsm #leusm 
Lymphoma Unit @Hospital_FJD & @UICOquironsalud. Board member @sehh_es & @EHA_Hematology. Chair, SWG “Aging and Hematology”. @ASH_hematology IMC member